Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
- Conditions
- Multiple Myeloma
- Registration Number
- NCT00131261
- Lead Sponsor
- Valerio Therapeutics
- Brief Summary
The purpose of this open-label, non-randomized trial is to assess the safety and effectiveness of PXD101, both alone and in combination with dexamethasone, in patients with advanced multiple myeloma. PXD101 is a new, potent histone deacetylase (HDAC) inhibitor. Various members of this class of drugs have shown activity in preclinical studies and in initial clinical trials of multiple myeloma and lymphoma. Furthermore, HDAC inhibitors, including PXD101, have been shown to sensitize myeloma cells to the killing effect of other chemotherapeutic agents, including dexamethasone, a well-established agent in relapsing myeloma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 25
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (7)
James Berenson, MD, Inc
🇺🇸West Hollywood, California, United States
H. Lee Moffitt Cancer Center
🇺🇸Tampa, Florida, United States
Northwestern University
🇺🇸Chicago, Illinois, United States
Research Facility
🇳🇴Trondheim, Norway
Rigshospitalet
🇩🇰Copenhagen, Denmark
Christie Hospital NHS Trust
🇬🇧Manchester, United Kingdom
The Royal Marsden NHS Trust
🇬🇧Surrey, United Kingdom
James Berenson, MD, Inc🇺🇸West Hollywood, California, United States